DÄ internationalArchive48/2007Progress in the Diagnostic Imaging and Treatment of Hepatocellular Carcinoma

Review article

Progress in the Diagnostic Imaging and Treatment of Hepatocellular Carcinoma

Dtsch Arztebl 2007; 104(48): A-3326

Trojan, J; Hammerstingl, R; Strey, C W; Vogl, T J; Bechstein, W; Zeuzem, S

For technical reasons, the English full text will be published approximately two weeks after the German print edition has been published.

1. El-Serag HB, Davila JA, Petersen NJ, McGlynn KA: The continuing increase in the incidence of hepatocellular carcinoma in the United States: an update. Ann Intern Med 2003; 139: 817–23. MEDLINE
2. Schurr R, Stolzel U, Schuppan D, Schwertner C, Steinberg J, Scherubl H: Zunahme des hepatozellulären und des intrahepatischen cholangiozellulären Karzinoms im Nordosten Deutschlands. Dtsch Med Wochenschr 2006; 131: 1649–55. MEDLINE
3. El-Serag HB, Hampel H, Javadi F: The association between diabetes and hepatocellular carcinoma: a systematic review of epidemiologic evidence. Clin Gastroenterol Hepatol 2006; 4: 369–80. MEDLINE
4. Hossain P, Kawar B, El Nahas M: Obesity and diabetes in the developing world – a growing challenge. N Engl J Med 2007; 356: 213–5. MEDLINE
5. Thomas MB, Abbruzzese JL: Opportunities for targeted therapies in hepatocellular carcinoma. J Clin Oncol 2005; 23: 8093–108. MEDLINE
6. Bruix J, Sherman M: Practice Guidelines Committee, American Association for the Study of Liver Diseases: Management of hepatocellular carcinoma. Hepatology 2005; 42: 1208–36. MEDLINE
7. McMahon BJ, Bulkow L, Harpster A et al.: Screening for hepatocellular carcinoma in Alaska natives infected with chronic hepatitis B: a 16-year population-based study. Hepatology 2000; 32: 842–6. MEDLINE
8. Foucher J, Chanteloup E, Vergniol J et al.: Diagnosis of cirrhosis by transient elastography (FibroScan): a prospective study. Gut 2006; 55: 403–8. MEDLINE
9. Friedrich-Rust M, Ong MF, Herrmann E et al.: Real-time elastography for noninvasive assessment of liver fibrosis in chronic viral hepatitis. Am J Roentgenol 2007; 188: 758–64. MEDLINE
10. Geier A, Gartung C, Staatz G, Nguyen HN, Matern S: Moderne Diagnostik benigner und maligner Raumforderungen der Leber. Dtsch Arztebl 2001; 98(47): A 3120–31. VOLLTEXT
11. Schima W, Hammerstingl R, Catalano C et al.: Quadruple-phase MDCT of the liver in patients with suspected hepatocellular carcinoma: effect of contrast material flow rate. Am J Roentgenol 2006; 186: 1571–9. MEDLINE
12. Hecht EM, Holland AE, Israel GM et al.: Hepatocellular carcinoma in the cirrhotic liver: gadolinium-enhanced 3D T1-weighted MR imaging as a stand-alone sequence for diagnosis. Radiology 2006; 239: 438–47. MEDLINE
13. Bellin MF: MR contrast agents, the old and the new. Eur J Radiol 2006; 60: 314–23. MEDLINE
14. Mazzaferro V, Regalia E, Doci R et al.: Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med 1996; 334: 693–9. MEDLINE
15. Jonas S, Bechstein WO, Steinmuller T et al.: Vascular invasion and histopathologic grading determine outcome after liver transplantation for hepatocellular carcinoma in cirrhosis. Hepatology 2001; 33: 1080–6. MEDLINE
16. Vogl TJ, Straub R, Eichler K, Woitaschek D, Mack MG: Malignant liver tumors treated with MR imaging-guided laser-induced thermotherapy: experience with complications in 899 patients (2,520 lesions). Radiology 2002; 225: 367–77. MEDLINE
17. Lencioni RA, Allgaier HP, Cioni D et al.: Small hepatocellular carcinoma in cirrhosis: randomized comparison of radio-frequency thermal ablation versus percutaneous ethanol injection. Radiology 2003; 228: 235–40. MEDLINE
18. Lin SM, Lin CJ, Lin CC, Hsu CW, Chen YC: Randomised controlled trial comparing percutaneous radiofrequency thermal ablation, percutaneous ethanol injection, and percutaneous acetic acid injection to treat hepatocellular carcinoma of 3 cm or less. Gut 2005; 54: 1151–6. Erratum in: Gut 2005; 54: 1508. MEDLINE
19. Llovet JM, Real MI, Montana X et al.: Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial. Lancet 2002; 359: 1734–9. MEDLINE
20. Takayasu K, Arii S, Ikai I et al.: Prospective cohort study of transarterial chemoembolization for unresectable hepatocellular carcinoma in 8,510 patients. Gastroenterology 2006; 131: 461–9. MEDLINE
21. Varela M, Real MI, Burrel M et al.: Chemoembolization of hepatocellular carcinoma with drug eluting beads: Efficacy and doxorubicin pharmacokinetics. J Hepatol 2007; 46: 474–81. MEDLINE
22. Yeo W, Mok TS, Zee B et al.: A randomized phase III study of doxorubicin versus cisplatin/interferon alpha-2b/doxorubicin/fluorouracil (PIAF) combination chemotherapy for unresectable hepatocellular carcinoma. J Natl Cancer Inst 2005; 97: 1532–8. MEDLINE
23. Becker G, Allgaier HP, Olschewski M, Zahringer A, Blum HE: Long-acting octreotide versus placebo for treatment of advanced HCC: A randomized controlled double-blind study. Hepatology 2007; 45: 9–15. MEDLINE
24. Kawata S, Yamasaki E, Nagase T et al.: Effect of pravastatin on survival in patients with advanced hepatocellular carcinoma. A randomized controlled trial. Brit J Cancer 2001; 84: 886–91. MEDLINE
25. Abou-Alfa GK, Schwartz L, Ricci S et al.: Phase II study of sorafenib in patients with advanced hepatocellular carcinoma. J Clin Oncol 2006; 24: 4293–300. MEDLINE
e1. Lin SM, Lin CJ, Lin CC, Hsu CW, Chen YC: Radiofrequency ablation improves prognosis compared with ethanol injection for hepatocellular carcinoma < or = 4 cm. Gastroenterology 2004; 127: 1714–23. MEDLINE
e2. Shiina S, Teratani T, Obi S et al.: A randomized controlled trial of radiofrequency ablation with ethanol injection for small hepatocellular carcinoma. Gastroenterology 2005; 129: 122–30. MEDLINE
e3. Tateishi R, Shiina S, Teratani T et al.: Percutaneous radiofrequency ablation for hepatocellular carcinoma. An analysis of 1000 cases. Cancer 2005; 103: 1201–9. MEDLINE
e4. Choi D, Lim HK, Rhim H et al.: Percutaneous radiofrequency ablation for early-stage hepatocellular carcinoma as a first-line treatment: long-term results and prognostic factors in a large single-institution series. Eur Radiol 2007; 17: 684–92. MEDLINE
e5. Philip PA, Mahoney MR, Allmer C et al.: Phase II study of Erlotinib (OSI-774) in patients with advanced hepatocellular cancer. J Clin Oncol 2005; 23: 6657–63. MEDLINE
e6. Zhu AX, Blaszkowsky LS, Ryan DP et al.: Phase II study of gemcitabine and oxaliplatin in combination with bevacizumab in patients with advanced hepatocellular carcinoma. J Clin Oncol 2006; 24: 1898–903. MEDLINE

Info

Specialities